ACUT — ACCUSTEM SCIENCES Share Price
Last trade - 00:00- $3.35m
- $3.39m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. The Company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The Company's product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company is focused on offering ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The Company's wholly owned subsidiary is StemPrintER Sciences Limited.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 28th, 2021
- Public Since
- March 1st, 2022
- No. of Shareholders
- 510
- No. of Employees
- 3
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 11,346,535
- Address
- 5 Penn Plaza, 19th Floor, #1954, NEW YORK, 10001
- Web
- https://accustem.com/
- Phone
- +1 2070661000
- Auditors
- Mazars USA LLP
Upcoming Events for ACUT
Similar to ACUT
Aamaxan Transport
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
Allied Healthcare Products
Pink Sheets on Nasdaq
FAQ
As of Today at 19:00 UTC, shares in ACCUSTEM SCIENCES are trading at $0.30. This share price information is delayed by 15 minutes.
Shares in ACCUSTEM SCIENCES last closed at $0.30 and the price had moved by -75.39% over the past 365 days. In terms of relative price strength the ACCUSTEM SCIENCES share price has underperformed the S&P500 Index by -78.29% over the past year.
There is no consensus recommendation for this security.
ACCUSTEM SCIENCES does not currently pay a dividend.
ACCUSTEM SCIENCES does not currently pay a dividend.
ACCUSTEM SCIENCES does not currently pay a dividend.
To buy shares in ACCUSTEM SCIENCES you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.30, shares in ACCUSTEM SCIENCES had a market capitalisation of $3.35m.
Here are the trading details for ACCUSTEM SCIENCES:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACUT
Based on an overall assessment of its quality, value and momentum ACCUSTEM SCIENCES is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ACCUSTEM SCIENCES. Over the past six months, its share price has underperformed the S&P500 Index by -67.34%.
As of the last closing price of $0.30, shares in ACCUSTEM SCIENCES were trading -65.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ACCUSTEM SCIENCES PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on ACCUSTEM SCIENCES' directors